Intrathecal drug delivery for treatment of chronic low back pain

Report from the National Outcomes Registry for Low Back Pain

Timothy Deer, Iva Chapple, Ashley Classen, Keith Javery, Valerie Stoker, Lisa Tonder, Kim Burchiel

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Objective. To obtain data on patient demographics, clinical practices, and long-term outcomes for patients with chronic low back pain treated with implantable drug-delivery systems. Design. The National Outcomes Registry for Low Back Pain collected data at baseline, trialing, implant (or decision not to implant), and at 6- and 12-month follow-ups. Data were collected at all time points, regardless of implant status. Outcome Measures. Numeric pain ratings and Oswestry Low Back Pain Disability scores from implanted patients were compared among baseline and 6- and 12-month follow-ups. Patients were also asked to rate their quality of life and satisfaction with the therapy. Results. Thirty-six physicians enrolled 166 patients to be trialed for drug-delivery systems. The trialing success rate was 93% (154 patients). In all, 136 patients (82%) were implanted. In the implant group, numeric pain ratings dropped by more than 47% for back pain and more than 31% for leg pain at the 12-month follow-up. More than 65% of implanted patients reduced their Oswestry scores by at least one level at their 12-month follow-ups compared with baseline. At 12-month follow-ups, 80% of implanted patients were satisfied with their therapy and 87% said they would undergo the procedure again. Conclusions. Current clinical practices related to trialing of drug-delivery systems resulted in the majority of patients successfully trialed. At 12 -month follow-ups, implanted patients experienced reductions in numeric back and leg pain ratings, improved Oswestry scores, and high satisfaction with the therapy.

Original languageEnglish (US)
Pages (from-to)6-13
Number of pages8
JournalPain Medicine
Volume5
Issue number1
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Low Back Pain
Registries
Pharmaceutical Preparations
Therapeutics
Back Pain
Drug Delivery Systems
Pain
Leg
Implantable Infusion Pumps
Quality of Life
Demography
Outcome Assessment (Health Care)
Physicians

Keywords

  • Intrathecal drug delivery
  • Low Back Pain
  • Outcomes
  • Registry

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Intrathecal drug delivery for treatment of chronic low back pain : Report from the National Outcomes Registry for Low Back Pain. / Deer, Timothy; Chapple, Iva; Classen, Ashley; Javery, Keith; Stoker, Valerie; Tonder, Lisa; Burchiel, Kim.

In: Pain Medicine, Vol. 5, No. 1, 03.2004, p. 6-13.

Research output: Contribution to journalArticle

Deer, Timothy ; Chapple, Iva ; Classen, Ashley ; Javery, Keith ; Stoker, Valerie ; Tonder, Lisa ; Burchiel, Kim. / Intrathecal drug delivery for treatment of chronic low back pain : Report from the National Outcomes Registry for Low Back Pain. In: Pain Medicine. 2004 ; Vol. 5, No. 1. pp. 6-13.
@article{f9b5d772b76944a08b9e90ca0e058f7c,
title = "Intrathecal drug delivery for treatment of chronic low back pain: Report from the National Outcomes Registry for Low Back Pain",
abstract = "Objective. To obtain data on patient demographics, clinical practices, and long-term outcomes for patients with chronic low back pain treated with implantable drug-delivery systems. Design. The National Outcomes Registry for Low Back Pain collected data at baseline, trialing, implant (or decision not to implant), and at 6- and 12-month follow-ups. Data were collected at all time points, regardless of implant status. Outcome Measures. Numeric pain ratings and Oswestry Low Back Pain Disability scores from implanted patients were compared among baseline and 6- and 12-month follow-ups. Patients were also asked to rate their quality of life and satisfaction with the therapy. Results. Thirty-six physicians enrolled 166 patients to be trialed for drug-delivery systems. The trialing success rate was 93{\%} (154 patients). In all, 136 patients (82{\%}) were implanted. In the implant group, numeric pain ratings dropped by more than 47{\%} for back pain and more than 31{\%} for leg pain at the 12-month follow-up. More than 65{\%} of implanted patients reduced their Oswestry scores by at least one level at their 12-month follow-ups compared with baseline. At 12-month follow-ups, 80{\%} of implanted patients were satisfied with their therapy and 87{\%} said they would undergo the procedure again. Conclusions. Current clinical practices related to trialing of drug-delivery systems resulted in the majority of patients successfully trialed. At 12 -month follow-ups, implanted patients experienced reductions in numeric back and leg pain ratings, improved Oswestry scores, and high satisfaction with the therapy.",
keywords = "Intrathecal drug delivery, Low Back Pain, Outcomes, Registry",
author = "Timothy Deer and Iva Chapple and Ashley Classen and Keith Javery and Valerie Stoker and Lisa Tonder and Kim Burchiel",
year = "2004",
month = "3",
doi = "10.1111/j.1526-4637.2004.04011.x",
language = "English (US)",
volume = "5",
pages = "6--13",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Intrathecal drug delivery for treatment of chronic low back pain

T2 - Report from the National Outcomes Registry for Low Back Pain

AU - Deer, Timothy

AU - Chapple, Iva

AU - Classen, Ashley

AU - Javery, Keith

AU - Stoker, Valerie

AU - Tonder, Lisa

AU - Burchiel, Kim

PY - 2004/3

Y1 - 2004/3

N2 - Objective. To obtain data on patient demographics, clinical practices, and long-term outcomes for patients with chronic low back pain treated with implantable drug-delivery systems. Design. The National Outcomes Registry for Low Back Pain collected data at baseline, trialing, implant (or decision not to implant), and at 6- and 12-month follow-ups. Data were collected at all time points, regardless of implant status. Outcome Measures. Numeric pain ratings and Oswestry Low Back Pain Disability scores from implanted patients were compared among baseline and 6- and 12-month follow-ups. Patients were also asked to rate their quality of life and satisfaction with the therapy. Results. Thirty-six physicians enrolled 166 patients to be trialed for drug-delivery systems. The trialing success rate was 93% (154 patients). In all, 136 patients (82%) were implanted. In the implant group, numeric pain ratings dropped by more than 47% for back pain and more than 31% for leg pain at the 12-month follow-up. More than 65% of implanted patients reduced their Oswestry scores by at least one level at their 12-month follow-ups compared with baseline. At 12-month follow-ups, 80% of implanted patients were satisfied with their therapy and 87% said they would undergo the procedure again. Conclusions. Current clinical practices related to trialing of drug-delivery systems resulted in the majority of patients successfully trialed. At 12 -month follow-ups, implanted patients experienced reductions in numeric back and leg pain ratings, improved Oswestry scores, and high satisfaction with the therapy.

AB - Objective. To obtain data on patient demographics, clinical practices, and long-term outcomes for patients with chronic low back pain treated with implantable drug-delivery systems. Design. The National Outcomes Registry for Low Back Pain collected data at baseline, trialing, implant (or decision not to implant), and at 6- and 12-month follow-ups. Data were collected at all time points, regardless of implant status. Outcome Measures. Numeric pain ratings and Oswestry Low Back Pain Disability scores from implanted patients were compared among baseline and 6- and 12-month follow-ups. Patients were also asked to rate their quality of life and satisfaction with the therapy. Results. Thirty-six physicians enrolled 166 patients to be trialed for drug-delivery systems. The trialing success rate was 93% (154 patients). In all, 136 patients (82%) were implanted. In the implant group, numeric pain ratings dropped by more than 47% for back pain and more than 31% for leg pain at the 12-month follow-up. More than 65% of implanted patients reduced their Oswestry scores by at least one level at their 12-month follow-ups compared with baseline. At 12-month follow-ups, 80% of implanted patients were satisfied with their therapy and 87% said they would undergo the procedure again. Conclusions. Current clinical practices related to trialing of drug-delivery systems resulted in the majority of patients successfully trialed. At 12 -month follow-ups, implanted patients experienced reductions in numeric back and leg pain ratings, improved Oswestry scores, and high satisfaction with the therapy.

KW - Intrathecal drug delivery

KW - Low Back Pain

KW - Outcomes

KW - Registry

UR - http://www.scopus.com/inward/record.url?scp=1642566729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642566729&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4637.2004.04011.x

DO - 10.1111/j.1526-4637.2004.04011.x

M3 - Article

VL - 5

SP - 6

EP - 13

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 1

ER -